Therapeutic poison
A team of scientists in Germany1 has identified a new protein from the venom of the snake, Vipera palaestinae, that could be used in the development of anti-cancer drugs.
A team of scientists in Germany1 has identified a new protein from the venom of the snake, Vipera palaestinae, that could be used in the development of anti‑cancer drugs.
The scientists performed affinity chromatography, using part of the α2β1 integrin as bait, to “pull-out” candidate toxins from a pool of venom. When this venom from the snake is injected into the victim, the toxins induce immobilization and, in most cases, death. The venom toxins target key receptors within the body that are also the targets of drug development.
Johannes Eble, co-author and professor at Frankfurt University Hospital, (Frankfurt, Germany), told The Column: “Poisonous venoms are cocktails consisting of a plethora of pharmacologically highly‑effective compounds directed against one or all of the essential organ systems”.
A previous study published in 2012, in the journal Nature, demonstrated that proteins biochemically isolated from the black mamba had potential pain-relieving effects in mice.2
Once biochemically isolated, individual venom compounds can possess strong and selective binding without the lethality. “This makes these evolutionarily optimized compounds ideal tools for basic research and lead structures to develop highly effective lead compounds for various disorders, such as hypertension, thrombosis and cancer,” according to Eble.
In this study, the search was for toxins that could inhibit the function of α2β1 integrin. A so-called “sticky protein”, it plays a key role in wound healing by aiding the aggregation of platelets. However, it also has a well-documented role in the inappropriate migration of cancer cells, metastasis. Consequently, this is a target for scientists developing drugs to inhibit metastasis.
The candidate toxin VP-1 was found to bind to the integrin, and subsequent testing proved that the toxin inhibited the migration of cancer cells in vitro.
The demonstration that VP-1 is able to bind and inhibit the α2β1 integrin presents a new model for the development of biotherapeutics for the inhibition of metastasis.
References
1. J. Eble et al, Toxicon DOI: 10.1016/j.toxicon. 2013.01.001 (2013).
2. S. Diochot et al, Nature DOI:10.1038/ nature11494 (2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
